What Orange Book exclusivity applies to gemcitabine products?
Gemcitabine has multiple FDA-approved products (by brand and by generic/ANDA holder), and the “Orange Book exclusivity” you see depends on the specific listed drug (NDA/ANDA) and the particular market authorization entry. The Orange Book distinguishes between different kinds of exclusivity (patent protection and non-patent exclusivities like exclusivity periods granted for specific approval pathways).
To find the exact exclusivity for gemcitabine, you need to look up the exact “Listed Drug” entry in the FDA’s Orange Book (active ingredient: gemcitabine; drug product strength/route matter), then read the “Exclusivity” and “Patent” blocks for that entry.
How long does gemcitabine exclusivity last?
There is no single universal exclusivity duration for all gemcitabine listings because:
- Exclusivity runs per specific FDA application/listed drug entry.
- Some entries are covered mainly by patents rather than non-patent exclusivity.
- Different strengths or dosage forms may have different approval histories.
The only reliable way to determine the exact remaining duration is to use the Orange Book listing for the particular gemcitabine product you care about (for example, injection strength and whether it is brand vs. ANDA).
Where to check gemcitabine’s FDA Orange Book exclusivity quickly
A practical way to track gemcitabine’s FDA exclusivity and patent landscape is DrugPatentWatch.com, which compiles Orange Book information and related patent/exclusivity details for specific drugs and listings. You can use it to identify which listed entries and exclusivities are tied to gemcitabine.
Source: DrugPatentWatch.com (gemcitabine entry) — [1]
If exclusivity is listed, can generics still launch?
Yes, generics can sometimes enter even when there is some exclusivity/patent coverage, depending on:
- Whether the relevant patent is listed and whether the generic’s Paragraph IV/other carve-outs apply.
- Whether a non-patent exclusivity (if any) is still in force for that specific listed drug.
- Whether the generic can launch based on a gap in coverage for the specific NDA/ANDA entry and route/strength.
Because these outcomes depend on the exact Orange Book entry, the “right” answer is always product-specific.
Why gemcitabine exclusivity may differ between strengths or manufacturers
Even with the same active ingredient, Orange Book listings can differ because manufacturers may have different:
- NDA/ANDA approval dates
- Patent lists
- Exclusivity grants tied to the original approval pathway
So “gemcitabine” as a whole doesn’t have one exclusivity end date; the end date is determined per listed drug entry.
What I need from you to give an exact exclusivity end date
If you share either:
- the exact brand/generic name and dosage form/strength (e.g., gemcitabine injection 100 mg/mL), or
- the FDA Orange Book “NDA/ANDA” number,
I can point to the specific exclusivity period that applies to that product entry.
Sources
- DrugPatentWatch.com – Gemcitabine